Astellas and Vir Biotechnology Enter Global Strategic Collaboration to Advance Prostate Cancer Treatment VIR-5500
This collaboration combines Astellas' oncology expertise and commercial reach with Vir's innovative PRO-XTEN platform, potentially accelerating the delivery of a new class of T-cell engager therapy for prostate cancer.
Astellas and Vir Biotechnology form a global strategic collaboration to co-develop and co-commercialize VIR-5500, a novel T-cell engager for prostate cancer, with Vir receiving $335M in initial payments.
Astellas Pharma and Vir Biotechnology have initiated a global strategic collaboration to co-develop and co-commercialize VIR-5500, a novel T-cell engager for treating prostate cancer. Vir Biotechnology will receive $335 million in initial payments. The partnership will share development costs, with Astellas leading future development and global commercialization. Vir Biotechnology retains co-promotion rights in the United States. This collaboration aims to accelerate the development of VIR-5500, which is currently in Phase I trials.
This collaboration combines Astellas' oncology expertise and commercial reach with Vir's innovative PRO-XTEN platform, potentially accelerating the delivery of a new class of T-cell engager therapy for prostate cancer. The deal structure allows both companies to share risk and reward, creating a strong incentive to advance VIR-5500 through clinical trials and into the market, addressing a significant unmet need in advanced prostate cancer treatment.
Where this signal fits in the broader landscape.
https://www.prnewswire.com/news-releases/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer-302694866.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In